Drug Profile
Valiloxybate - XWPharma
Alternative Names: XW-10172Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator XW labs
- Developer XWPharma
- Class Neuroprotectants; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Narcolepsy
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Narcolepsy(In volunteers, In adults) in Australia (PO, Controlled release)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Narcolepsy(In volunteers, In adults) in Australia (PO, Immediate release)
- 14 Jun 2021 XWPharma plans a single phase III pivotal trial for Narcolepsy (PO), in 2021